Novo NordiskNVO
About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Employees: 77,406
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
13% more repeat investments, than reductions
Existing positions increased: 614 | Existing positions reduced: 541
0.42% less ownership
Funds ownership: 9.94% [Q4 2024] → 9.52% (-0.42%) [Q1 2025]
9% less funds holding
Funds holding: 1,637 [Q4 2024] → 1,491 (-146) [Q1 2025]
23% less funds holding in top 10
Funds holding in top 10: 31 [Q4 2024] → 24 (-7) [Q1 2025]
24% less capital invested
Capital invested by funds: $30.1B [Q4 2024] → $23B (-$7.1B) [Q1 2025]
26% less call options, than puts
Call options by funds: $987M | Put options by funds: $1.34B
43% less first-time investments, than exits
New positions opened: 139 | Existing positions closed: 242
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
BMO Capital Evan David Seigerman | 6%downside $64 | Market Perform Downgraded | 17 Apr 2025 |
Financial journalist opinion
Based on 165 articles about NVO published over the past 30 days









